Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference [Yahoo! F...
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Yahoo! Finance
mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced acceptance of a late-breaking oral presentation of data from its ongoing RestorAATion-2 clinical trial of WVE-006, its investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic Society (ATS) International Conference taking place in Orlando, Florida during May 15-20, 2026. Wave now expects to share data from the 600 mg single dose cohort in addition to data from the 400 mg multidose cohort at the ATS conference in May. “The annual ATS conference is an important forum for fostering innovation in pulmonary care, and we are excited to have the opportunity to share data from our Restor
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International ConferenceGlobeNewswire
- WAVE Life Sciences (WVE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Wave Life Sciences Teases Near-Term Obesity and RNA Editing Data as INLIGHT Readouts Near [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Ltd. (WVE): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Wave Life Sciences Ltd. (WVE) Announces Fiscal Q4 and Full-Year 2025 Earnings [Yahoo! Finance]Yahoo! Finance
WVE
Earnings
- 2/26/26 - Miss
WVE
Sec Filings
- 2/27/26 - Form 4
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- WVE's page on the SEC website